Immunai

Immunai is a biotechnology business that use artificial intelligence (AI) and machine learning to evaluate vast quantities of immune system data. The company's mission is to advance the knowledge of the immune system and to provide innovative therapies for illnesses such as cancer, autoimmune disorders, and infectious diseases.

Using a mix of single-cell genomics and AI, Immunai's technology analyses data from millions of individual immune cells. This information is used to generate a "map" of the immune system, illustrating how various cells and pathways work together to combat illness. Immune Intelligence Platform is the name of the company's platform, which enables researchers to examine data from numerous sources, including genomes, transcriptomics, and proteomics, in order to uncover novel targets for drug development and new biomarkers for illness detection.

Immunai's technology is also used to evaluate data from clinical trials, select patients most likely to react to a specific medication, and track patients' responses to treatment over time.

Immunai is one of the top firms in the field of AI-based immune system research, and its technology is utilised by several pharmaceutical companies, academic institutions, and research institutes to advance the knowledge and treatment of illnesses.

‍